Antifungal Drugs | The Medical Letter Inc.

Treatment Guidelines from The Medical Letter

FROM
ISSUE

120

August 1, 2012

View Complete Issue Table of Contents 2019

Antifungal Drugs

Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article.

Antifungal Drugs

August 1, 2012 (Issue: 120)

The drugs of choice for treatment of fungal infections are listed in the table that begins on page 62. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections...more

Show References Hide References

1. LJ Wheat et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807.

2. FDA. FDA drug safety communication: use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants. Available at www.fda.gov/Drugs/DrugSafety/ucm266030.htm. Accessed July 2, 2012.

3. Arizona Center for Education and Research on Therapeutics. Drugs that prolong the QT interval and/or induce torsades de pointes ventricular arrhythmia. Available at www.azcert.org. Accessed July 2, 2012.

4. CYP3A and drug interactions. Med Lett Drugs Ther 2005; 47:54.

5. R Herbrecht et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408.

6. J Smith et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570.

7. A Pascaul et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201.

8. TF Wang et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant 2009; 9:2845.

9. RA Wermers et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 2011; 52:604.

10. EW Cowen et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62:31.

11. DD Miller et al. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146:300.

12. V Hafner et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother 2010; 54:2596.

13. D Neofytos et al. Administration of voriconazole in patients with renal dysfunction. Clin Infect Dis 2012; 54:913.

14. DJ Skiest et al. Posaconazole for the treatment of azole-refractory-oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44:607.

15. TJ Walsh et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2.

16. A Catanzaro et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007; 45:562.

17. DA Stevens et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007; 132:952.

18. JA Van Burik et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42:e61.

19. B Spellberg et al. Novel perspectives on mucormycosis: pathophysiology, presentation and management. Clin Microbiol Rev 2005; 18:556.

20. C Wagner et al. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006; 78:161.

21. J Mora-Duarte et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020.

22. J Maertens et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563.

23. ER Kuse et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519.

24. PG Pappas et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883.

25. AC Reboli et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472.

26. MM Roden. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis 2003; 36:1213.

27. KA Marr et al. A randomized double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. Poster presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). London, UK. March-April 2012.

28. JR Wingard et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogenic hematopoietic cell transplantation. Blood 2010; 116:5111.

29. AG Freifeld et al. Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Disease Society of America. Clin Infect Dis 2011; 52:e56.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.